ClinicalTrials.gg
Drug

IT-101 clinical trials

Also written CRLX101 and NLG207.

studies test it
15
open now
0
in phase 3
0
first study started
2006

How each study uses IT-101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

cyclodextrin-based polymer-camptothecin CRLX101
2
cyclodextrin-based polymer-camptothecin IT-101
2

Development codes

CRLX101
10
NLG207
5
IT-101
4
EP0057
3

Studies by the year they started

15 studies that test it; most in 2012 (3)

Studies that test IT-101, by start year
YearStudies
20061
20081
20111
20123
20132
20141
20152
20161
20191
20201
20231

By phase

A phase 1/2 study counts in both.

Phase 1
6
Phase 2
13

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 8 · Other 7

NewLink Genetics Corporation (6) · Ellipses Pharma (2) · National Cancer Institute (NCI) (2) · Abramson Cancer Center at Penn Medicine (1) · Massachusetts General Hospital (1) · City of Hope Medical Center (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Chicago (1)

Often tested with

Tested in the same studies.

Bevacizumab (1) · Capecitabine (1)

Studies

Open first, then newest update. How each study uses IT-101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 15